 |
Imatinib mesylate |
|---|---|
| Trade Name | Gleevec |
| Orphan Indication | Myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements |
| USA Market Approval | USA |
| USA Designation Date | 2005-10-05 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;One Health Plaza, Mail Code 105/1E870D;East Hanover, New Jersey, 07936 |
